Reversible Parkinsonism linked to trimetazidine.
A dozen cases of Parkinsonism linked to trimetazidine use have been reported in Spain. The symptoms resolved after treatment was stopped. Given trimetazidine's lack of established benefits, nothing justifies exposing patients to the least risk of this sort.
D000368:Aged; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D020734:Parkinsonian Disorders / Q000139:chemically induced*; D013030:Spain; D014292:Trimetazidine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D014665:Vasodilator Agents; D014292:Trimetazidine